IGF1 and Hyperkeratosis: Hyperinsulinemia in AN patients may increase the binding of insulin and IGF-R and may also reduce IGF-binding proteins (IGFBPs), thus increasing biologically active IGF-1; this results in the development of hyperkeratosis and papillomatosis [6,35,36,37].